The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS- 10504 tablets", a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced non-small cell lung cancer. The specific indication will be determined after the completion of clinical research.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.88 HKD | +0.34% | -2.40% | +13.45% |
Apr. 30 | Hansoh Pharmaceutical’s 2023 Profit Up 27% | MT |
Apr. 29 | Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+13.45% | 13.56B | |
+31.37% | 588B | |
-2.76% | 364B | |
+20.66% | 326B | |
+5.66% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+11.19% | 167B | |
-0.02% | 161B |
- Stock Market
- Equities
- 3692 Stock
- News Hansoh Pharmaceutical Group Company Limited
- Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung Cancer